Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 30

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 30
---
 may receive up to $25 million in gross proceeds from Keystone in connection with the sale of our Common Stock under the Keystone Purchase Agreements. We intend to use any net proceeds from any sales of shares of our Common Stock to Keystone under the Keystone Equity Financing for working capital and other general corporate purposes. Pending other uses, we intend to invest the net proceeds to us in investment-grade, interest-bearing securities such as money market funds, certificates of deposit, or direct or guaranteed obligations of the U.S. government, or hold as cash. We cannot predict whether the net proceeds invested will yield a favorable return. See “Use of Proceeds.” |
| Common Stock ticker symbol                                             |     | “CERO”                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| Risk factors                                                           |     | Any investment in the securities offered hereby is speculative and involves a high degree of risk. You should carefully consider the information set forth under “Risk Factors” and elsewhere in this prospectus.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |

9 RISK FACTORS Investing in our securities involves a high degree of risk. Before you decide to invest in our securities, you should consider carefully the risks described below, together with the other information contained in this prospectus, including our financial statements and the related notes appearing at the end of this prospectus. We believe the risks described below are the risks that are material to us as of the date of this prospectus. If any of the following risks actually occur, our business, results of operations and financial condition would likely be materially and adversely affected. In these circumstances, the market price of our securities could decline, and you may lose part or all of your investment. Risks Related to the Keystone Equity Financing It is not possible to predict the actual number of shares of our Common Stock, if any, we will sell under the Keystone Purchase Agreements, or the actual gross proceeds resulting from those sales or the dilution to you from those sales. Further, we may not have access to the full amount available under the Keystone Purchase Agreements. Pursuant to the Keystone Purchase Agreements, Keystone shall purchase from us up to $25 million of shares (the “Keystone Commitment Amount”). As of the date of this prospectus, we have issued and sold 12,612,270 shares of Common Stock for aggregate proceeds of $10,408,061 pursuant to the Keystone Equity Financing, which includes 11,689 shares of Common Stock pursuant to the February 2024 Keystone Purchase Agreement, 100,581 shares of Common Stock